Showing results (111-120 of 315) with videos related to

Sort By:
Pageof 32
Journal of Chromatographic Science|November 1, 1982
HPLC, MS, and pharmacokinetics of melphalan, bisantrene and 13-cis retinoic acidT P Davis, Y M Peng, G E Goodman, et al.
British Journal of Cancer|August 1, 1978
Effect of phenobarbital on plasma levels of cyclophosphamide and its metabolites in the mouseD S Alberts, Y M Peng, H S Chen, et al.
Gynecologic Oncology|June 1, 1987
Tamoxifen therapy in recurrent epithelial ovarian carcinomaS A Weiner, D S Alberts, E A Surwit, et al.
Cancer Treatment Reports|March 1, 1987
Experimental dacarbazine antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotesR T Dorr, D S Alberts, J Einspahr, et al.
American Journal of Clinical Oncology|October 1, 1984
Mitoxantrone in epithelial carcinoma of the ovary. A Southwest Oncology Group studyR D Hilgers, S E Rivkin, D D Von Hoff, et al.
Cancer Treatment Reports|January 1, 1981
New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assayS E Salmon, F L Meyskens, D S Alberts, et al.
Gynecologic Oncology|August 7, 2007
Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group studyL M Hess, R Barakat, C Tian, et al.
Cancer Research|October 1, 1985
Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantreneG T Bowden, R Roberts, D S Alberts, et al.
The Journal of Antibiotics|June 1, 1982
Aculeacin A resistant mutants of Candida albicansR J Mehta, C H Nash, S F Grappel, et al.
Investigational New Drugs|January 1, 1985
Pharmacology of mitoxantrone: mode of action and pharmacokineticsD S Alberts, Y M Peng, G T Bowden, et al.
Pageof 32